Physician profile
Alok Rustogi
NPI 1730116575
$8,993.89
in general payments reported to CMS, 2019-2025
39 companies · $2,160 in 2025
The $2,160 reported for 2025 was more than what 95% of Adolescent Medicine (Internal Medicine) providers received nationally (typical 2025 total: $165).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $1,406 · 2021: $904 · 2022: $846 · 2023: $1,170 · 2024: $1,555 · 2025: $2,160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,885.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,574.37 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,166.49 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,137.71 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Amgen INC. | $648.13 | 2023-2025 | Otezla, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $478.72 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $442.13 | 2021-2025 | |
| Glaxosmithkline, LLC. | $428.11 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $390.15 | 2019-2025 | |
| Lilly USA, LLC | $332.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $317.52 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $211.68 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $188.12 | 2023-2024 | Aptiom, Gemtesa |
| Astellas Pharma US INC | $182.23 | 2019-2024 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.74 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $120.06 | 2019-2022 |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alok Rustogi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.